Predictive value of neutrophil-lymphocyte ratio for prognosis in patients with advanced hepatocellular carcinoma treated with programmed cell death 1 inhibitors

Table 10 Cox proportional hazards regression analysis of factors influencing overall survival in patients with advanced hepatocellular carcinoma treated with programmed cell death protein 1 inhibitors

Variable	Univariate		Multivariate
	HR (95%CI)	P value	HR (95%CI)	P value
BCLC stage (C vs B)	2.148 (1.421-3.255)	< 0.001	1.763 (1.144-2.715)	0.010
Child-Pugh grade (B vs A)	1.681 (1.171-2.413)	0.005	1.405 (0.963-2.051)	0.077
Maximum tumor diameter (per 1 cm increase)	1.352 (1.207-1.514)	< 0.001	1.241 (1.102-1.398)	< 0.001
Macrovascular invasion (yes vs no)	1.892 (1.347-2.654)	< 0.001	1.475 (1.034-2.105)	0.032
Extrahepatic spread (yes vs no)	1.821 (1.271-2.607)	0.001	1.521 (1.044-2.216)	0.029
AFP (≥ 400 ng/mL vs < 400 ng/mL)	2.241 (1.578-3.183)	< 0.001	1.847 (1.281-2.663)	0.001
NLR (high vs low)	2.861 (2.001-4.091)	< 0.001	2.421 (1.667-3.516)	< 0.001
AST (≥ 40 U/L vs < 40 U/L)	1.578 (1.121-2.225)	0.009	1.318 (0.924-1.889)	0.128
Total bilirubin (≥ 20 μmol/L vs < 20 μmol/L)	1.518 (1.082-2.139)	0.016	1.261 (0.884-1.799)	0.202
Albumin (≥ 35 g/L vs < 35 g/L)	0.652 (0.461-0.923)	0.016	0.745 (0.521-1.067)	0.108

BCLC: Barcelona Clinic Liver Cancer; AFP: Alpha fetoprotein; NLR: Neutrophil-to-lymphocyte ratio; AST: Aspartate aminotransferase; HR: Hazard ratio; CI: Confidence interval.